Implant Sciences QS-B220 explosives trace detector approved for passenger and baggage screening at U.S. airports QS-B220 now on TSA's Qualified Products List
WILMINGTON, Mass., Aug. 28, 2014 /PRNewswire/ -- Marking a major milestone for the Company, Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 desktop explosives trace detector has successfully completed the certification process for the United States Transportation Security Administration's (TSA) Explosive Trace Detection (ETD) qualification requirements for aviation checkpoint and checked baggage screening. The QS-B220 becomes the first ETD with a non-radioactive source to be added to the TSA's Qualified Product List (QPL).
"The addition of the QS-B220 to TSA's QPL is the single most significant achievement in our Company's history," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "We're very proud to be able to deliver this innovative product for the protection of travelers in our country. Every member of the Implant Sciences team has done a phenomenal job of getting us to this point. We would also like to recognize the support we have received from our shareholders and other investors over the last few years while we have been pursuing this most significant qualification. Without their support this would not have been achievable."
"Being added to TSA's QPL is one of the highest levels of recognition in the security industry and one of the most difficult to achieve. The team at Implant Sciences has been nothing short of remarkable and focused in preparing the QS-B220 for this challenge," continued Todd Silvestri, VP of Technology for Implant Sciences Corporation. "Implant Sciences has highlighted their deep domain knowledge in the development and commercialization of this unit, and we are excited as a company to have cleared the last major hurdle in the U.S. aviation market."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide. Implant Sciences is only the third manufacturer, and the sole American-owned company, to currently have an ETD system named as a Qualified Product by the US Transportation Security Administration. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation